Targeting Fibrosis for the Treatment of Heart Failure: A Role for Transforming Growth Factor-beta
Amanda J Edgley, Henry Krum, Darren J Kelly
Cardiovascular Therapeutics | WILEY | Published : 2012
Henry Krum: HK has received grant and research support within the past 12 months from National Health and Medical Research Council, Medtronic, Scios, BUPA, Pfizer, and GlaxoSmithKline, and consultancy and speaker honoraria from Amgen, AstraZeneca, Medtronic, St Jude Medical, Roche, Novartis, Sanofi-Aventis, Pfizer, Mesoblast, and Gilead. HK is a member of the following advisory boards: Biotronik, Novartis, Sanofi - Aventis, Pfizer, Mesoblast, Apollo Life Sciences, and Gilead.Darren Kelly: DJK has received grant and research support within the past 12 months from National Health and Medical Research Council and Diabetes Australia Research Trust. Honoraria and grants from Novartis, Eli Lilly and Mesoblast. DJK is a director of Fibrotech Therapeutics.